When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CNAT - Conatus down 27% on second failed emricasan study
Conatus Pharmaceuticals
Conatus Pharmaceuticals (CNAT-27.2%) slumps on double normal volume in reaction to results from a Phase 2 clinical trial, ENCORE-PH, evaluating emricasan in NASH patients with cirrhosis and severe portal hypertension. The data were presented at The International Liver Congress in Vienna.
More news on: Conatus Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move,